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Abstract Background Humanmilk feeding protects against oxidative stress-induced damage in
preterm neonates, including severe multifactorial diseases such as retinopathy of
prematurity (ROP), necrotizing enterocolitis (NEC), and bronchopulmonary dysplasia
(BPD). The carotenoids, which are not found in formula milk, might play a key role in
these actions.
Methods A multicenter, double-blind, randomized controlled trial was conducted in
three tertiary Italian neonatal intensive care units. All preterm infants <32+6 weeks’
gestational age were eligible and were randomized to a single, oral, daily 0.5-mL dose of
carotenoid supplementation (0.14 mg lutein + 0.0006 mg zeaxanthin) or placebo (5%
glucose solution) from birth till 36 weeks’ corrected gestational age. Primary outcomes
were threshold ROP, NEC > second stage, and BPD. Surveillance for detection of these
diseases and for intolerance/adverse effects was performed.
Results No treatment-related adverse effect was documented in the 229 analyzed
infants, whose clinical/demographical characteristics were similar in the two groups.
Threshold ROP incidence did not significantly differ in treated (6.2%) versus not treated
infants (10.3%; p ¼ 0.18). The same occurred for NEC (1.7% versus 5.1%; p ¼ 0.15) and
BPD (4.5% versus 10.3%; p ¼ 0.07). Noteworthy, the progression rate from early ROP
stages to threshold ROP was decreased by 50% (0.30 versus 0.44; p ¼ 0.23).
Conclusion Lutein/zeaxanthin supplementation in preterm infants is well tolerated.
No significant effect was seen on threshold ROP, NEC, or BPD. The decreasing trends of
these outcomes in the treatment group need to be assessed and confirmed on larger
sample-sizes.
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Progress in perinatal care has improved survival rates among
preterm neonates. However, disability-free survival from
preterm birth is increasingly hampered by several adverse,
long-term outcomes of prematurity such as retinopathy of
prematurity (ROP), necrotizing enterocolitis (NEC) and bron-
chopulmonary dysplasia (BPD).1
Prematurity itself plays the major role in such multifacto-
rial late diseases. However, oxidative stress-induced damage
related both to prematurity and to the type of care adminis-
tered is speculated to play an important, additional role.2 As
these preterm infants are susceptible to oxidative damage
due to high metabolic rate and low levels of antioxidant
enzymes, and this is a crucial step for the onset of many
severe outcomes of prematurity, efforts have been addressed
to the identification of protective strategies that will enhance
their antioxidant functions.3
Maternal milk feeding is indicated for all premature in-
fants as it provides valuable nutritional and immunologic
benefits.4 Noteworthy, human milk is also protective toward
some severe outcomes of prematurity such as sepsis,4 ROP,5
BPD, and NEC.6
The observation that fresh human milk is rich in many
antioxidants7 (e.g., vitamin E, β-carotene, lutein, and lacto-
ferrin) helps understand why human milk has is protective
against many multifactorial diseases in which an oxidative
stress-induced damage occurs (e.g., ROP, NEC, and BPD).
Among the antioxidant factors of human milk, the caro-
tenoids (lutein, β-carotene, zeaxanthin, lycopene) are be-
lieved to play a crucial role.8 Carotenoids, a family of
polyene lipophilic molecules, are not found in formulas.
Colostrum contains a very high level of carotenoids, particu-
larly of lutein (up to 140 μg/L) that is fivefold that of mature
milk.9 Carotenoids provide protection against both light-
induced and metabolic oxidative damage in the premature
retina, and protection from oxidative stress in other develop-
ing tissues where oxidative insults occur.
As nutritional supplements, lutein and zeaxanthin were
granted a generally recognized as safe (GRAS) status by the
Food and Drug Administration in June 2004 (see GRAS
Notice No. GNR 000140 issued by Center for Food Safety
and Applied Nutrition/Office of Food Additive Safety10).
On this ground, these two carotenoids are currently
marketed worldwide, but only in some countries is lutein-
supplemented formula milk available.
The present study assesses the outcomes of preterm infants
given supplemented carotenoids (lutein and zeaxanthin)
during their stay in the neonatal intensive care unit (NICU),
as well as the safety and tolerability of these two supplements.
Methods
This study is a multicenter, prospective, randomized, double-
blind, placebo-controlled trial conducted over a 12-month
period in three NICUs of northern Italy.
All neonates with gestational age<32 weeks + 6 days (i.e.,
all those qualifying for screening of ROP) born within the
study period, whether at one of the participant institutions or
elsewhere, were eligible for the study. Parental refusal,
admission after 48 hours of life, death prior to 72 hours of
life, ophthalmologic disease already present at the time of
randomization were exclusion criteria.
The primary objective of the study was to evaluate the
effectiveness of the lutein + zeaxanthin supplementation,
compared with placebo, in the prevention of threshold ROP,
BPD, and necrotizing enterocolitis (NEC) of surgical stage
(i.e., second or greater according to Bell’s classification11).
Secondary objectiveswere the assessment of the incidence
of ROP of all stages, NEC of all stages; of intestinal perforation;
of late-onset sepsis; of mortality prior to discharge; of severe
(grade 3 to 4) intraventricular hemorrhage; of need for
transfusions; of liver failure defined as 3 elevation of normal
serum liver enzymes values.
Surveillance for detection of all these outcomes, as well as
for episodes of intolerance to the supplements or adverse
effects, was performed till discharge or term corrected age,
whichever came first. Measurements of serum liver enzymes
values were performed at 4 weeks of age.
Infants were randomly allocated to one of two groups in a
1:1 ratio to receive carotenoids oral supplementation (group
A) or placebo (group B). Randomization was stratified by
center, and randomly permuted blocks of size 9 and 12 were
used. The random allocation sequence was generated using
ralloc.ado version 3.2.5 in Stata 9.2 (Stata-Corp, College
Station, TX). The pharmacy at each center used these com-
puter-generated randomization lists to form the two groups
and prepared the drug doses in sealed opaque vials.
In detail, the study intervention consisted of daily oral
administration of a mixture containing 0.14 mg of lutein and
0.0006 mg of zeaxanthin (equal to 0.5 mL of the product
LuteinOfta gtt, NEOOX Division of SOOFT Italia SpA, Monte-
giorgio, Italy) in group A infants, whereas group B infants
received a daily oral administration of 0.5 mL of 5% glucose
solution as placebo. Clinical and research staff remained
unaware of study group assignments during the study.
As mentioned, the supplemented drug and placebo were
administered in a single oral daily dose frombirth till week 36
of gestational (corrected) age, starting from the first 48 hours
of life.
Neonates not feeding in the first 48 hours received the
drug/placebo by oral/nasogastric tube and were enrolled in
the absence of gastric instability and/or repeated gastric
residuals or emesis. If they repeatedly displayed gastric
instability, gastric residuals, or vomit, they were enrolled at
any point during the first week of life, depending on the first
“efficacious” feedings. The day of life in which they first
received the drugs or placebo was recorded in the database,
and their statistics were limited to the days of administration/
exposure to the intervention.
Nutritional and feeding policies followed common proto-
cols. Administration of fresh, expressed maternal milk was
encouraged. Each mother could supply milk only for
her infant. When needed, feeding was supplemented
with a formula for very low-birth-weight (VLBW) infants
(PreAptamil; Milupa Italia, Milano, Italy) not supplemented
with lutein or zeaxanthin. Systematic surveillance of adverse
events (e.g., vomiting, feeding intolerance, skin rashes) was
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performed through daily infant examination until 2 days after
end of treatment.
SOOFT Italia SpA supplied the lutein + zeaxanthin prepa-
rations, as well as the placebo in identical vials.
Definitions of Outcomes
NEC was defined as clinical signs with the presence of
Pneumatosis intestinalis on abdominal X-rays, according to
the Bell criteria.11
Severe BPDwas defined as use of supplemental oxygen for
28 days plus 30% oxygen, positive pressure ventilation at
36 weeks’ postmenstrual age, or both.12
ROP was defined according to the Early Treatment for
Retinopathy of prematurity study.13 Ophthalmologic screen-
ing for ROP was performed by one board-certified consultant
ophthalmologist in each participating unit. Infants were first
screened at 3 to 4 weeks of age and then at 1- to 2-week
intervals, depending on the clinical picture and the severity of
retinopathy at the discretion of the ophthalmologist and
neonatologist. All infants were examined until regression of
the ROP lesions, or until retinal vascularizationwas complete.
In case of discharge prior to the week 36 of gestational age,
infants with ongoing not threshold ROP lesions were consid-
ered still at risk of progression to more severe stages, and
therefore the screening was not discontinued. The infants
were revisited also after discharge by the same ophthalmol-
ogists in the hospital unit, at scheduled intervals, until either
the development of ROP or the disappearance of the lesions.
Gestational age was calculated using the expected date of
delivery based on an ultrasound performed before 22 weeks’
gestation or—when ultrasound was not available—was deter-
mined by the attending neonatologist when the infant was
admitted to the NICU based on neonatal clinical findings.
Neonates were all classified by their most severe ROP
examination.
The screening ophthalmologistswere unaware of treatment
assignments or any other potential risk factors for ROP other
than VLBWor gestational age 32 weeks. The decision to treat
ROP was always taken according to the stage of the disease.
Late-onset sepsis was defined as occurring more than
72 hours after birth and before discharge. This condition
was based on the detection of clinical signs and symptoms
by the physician in charge, presence of laboratory findings
consistent with sepsis, and isolation of a causative organism
from blood (drawn from peripheral sites) or cerebrospinal or
peritoneal fluid.14,15 Diagnostic criteria were based on the
existing literature, guidelines from international consensus
documents, and recommendations from the Italian Neona-
tology Society’s Fungal Infections Task Force.16,17
Presence and grade of intraventricular hemorrhage were
documented by the most negative ultrasound finding avail-
able; intraventricular hemorrhage was classified by the Papile
criteria.18
Statistical Analysis
All primary and secondary outcomes were represented by
dichotomous variables (presence/absence) and analyzed by
intention-to-treat.
Categorical predictor variables were represented by per-
centages. Birth weight, gestational age, Apgar score, number
of days receiving a given treatment, and daily amount of milk
intake were represented by continuous variables. A complete
list of the categorical and continuous variables considered is
shown in ►Table 1.
Proportions and continuous variables were compared using
the Fisher exact two-tailed test and the t test, respectively. Risk
ratios and 95% confidence intervals were calculated to compare
cumulative between group incidences using Stata version 9.2.
The Wald test was used to assess the significance of the
estimated coefficients. The likelihood ratio test was used to
test the significance of the center-level variance component.
Goodness-of-fit was evaluated through the log-likelihood of
the fitted model. All tests were two-tailed, and p < 0.05 was
considered statistically significant.
Sample size analysis predicted that 114 patients would be
needed for each group, based on two-sided type I error rates
of 0.05 or less and 80% power to detect a relative difference
between treated and nontreated infants of at least 66%
(decrease from 18 to 6%, given a pretrial incidence of
18%15) for threshold ROP.
A total of 638 and 376 infants in each group would have
been needed to detect the same extent of significant differ-
ences between groups for BPD and NEC, given pretrial inci-
dences of 3.6% and 6.0%, respectively. Given the low incidence
of these last two outcomes in our pretrial data, the study was
underpowered to detect possible significant differences.
Power calculations were performed according to S plus,
Version 2000. Analysis of dichotomous outcomes and inter-
pretation of results were performed as suggested in Cochrane
Reviewers’ Handbook 4.2.2.19
SOOFT Italia SpA provided financial support with a grant
but was not involved in the concept, design, enrollment, data
collection, analysis and interpretation of its results, and
decisions inherent the publication of the results.
Results
Of 247 VLBW infants considered for inclusion in the trial
(►Fig. 1), 18 were not eligible either because they did not
meet inclusion criteria (n ¼ 1) or because the parents refused
to participate (n ¼ 14), or for other reasons (n ¼ 3).
One infant in group A did not receive all the study doses,
and four infants (two in group A and two in group B) had
incomplete data, but all of them were included in the final
analysis on an intent-to-treat basis.
The final analysis included 229 infants, 113 in group A and
116 in B. Clinical and demographic characteristics did not
differ between the two groups (►Table 1).
Results of the study outcomes are reported in ►Table 2.
Overall, threshold ROP incidence tended to be lower in the
treated (6.2%) versus not treated (10.3%) infants (p ¼ 0.18).
The same occurred for BPD (4.5% versus 10.3%; p ¼ 0.15) and
NEC (1.7 versus 5.1%; p ¼ 0.07). Of note, treatment was
associated with a lower rate of progression from the early
stages of ROP to the threshold stage (0.30 versus 0.44;
p ¼ 0.23).
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No significant differences were seen also when clustering
the analysis for type of infant feeding (human fresh milk
versus formula milk).
Serum liver enzymes values at 4 weeks of agewere normal
and comparable in the two groups (►Table 3). Liver
function evaluations did not disclose any hepatic adverse
effect putatively attributable to the supplementation in any
moments.
No adverse effects putatively attributable to the treatment
was documented.
Discussion
To our knowledge, this is the first randomized controlled trial
(RCT) assessing the outcomes of preterm infants given a
carotenoid supplementation since birth.
Table 1 Demographics and Clinical Characteristics
Group A: Lutein
(n ¼ 113)
Group B: Placebo
(n ¼ 116)
p Value
Group A versus
Group B
Demographics
Birth weight (g), mean  SD (range) 1336  417
(560–1485)
1271  386
(600–1500)
0.29
Gestational age (wk), mean  SD (range) 30.1  1.8
(24–34)
29.7  2.6
(25–34)
0.45
Sex (male/female) 44 56
Race (% of Caucasian) 85% 89% 0.90
Born at another facility (%) 16 21 0.39
Vaginal delivery (%) 22 29 0.40
Mother had preeclampsia (%) 21 26 0.55
Premature rupture of membranes 23 25 0.99
Use of antenatal corticosteroids 63 64 0.89
Use of antenatal antibiotics 70 73 0.99
Clinical characteristics
Mean Apgar score at 5 min. 7.3 7.3 0.69
Use of surfactant (at least once) 61 68 0.26
Umbilical catheter positioned (d) 4.3 4.7 0.90
Intubation (d) 5.6 7.0 0.42
Mechanical ventilation (total d) 7.9 10.8 0.06
Supplemental oxygen (total d) 9.6 12.9 0.25
Incidence of early-onset neutropenia (%) 8.5 9 0.80
Use of TPN (d) 9.8 13.6 0.05
H2 blockers (total d) 5.3 6.4 0.40
Third-generation cephalosporins (total d) 3.5 4.1 0.88
Antibiotics (total d) 12.6 15.4 0.19
Postnatal steroids (total d) 0.4 1.2 0.07
Mean duration of stay in NICU (d) 42 45 0.99
Central venous catheter(s) positioned (d) 16.4 20.1 0.10
Nutritional characteristics
Time of initiation of oral feeding (DOL) 3.3 3.8 0.14
Time of achievement of full feeding (DOL) 12.7 14.3 0.25
Mean volume of feedings advancements daily (mL/d) 10.0 10.5 0.69
Proportions of infants fed with only formula 19% 17% 0.70
Daily average amounts of human fresh milk intake (mL/kg) 68.5 65.0 0.99
Total days of human fresh milk feeding 30 29 0.99
DOL, day of life; NICU, neonatal intensive care unit; SD, standard deviation; TPN, total parenteral nutrition.
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Screened and assessed  
for eligibility (n = 247)
Excluded (n = 18) 
• Not meeting inclusion 
criteria (n = 1) 
• Refused to participate 
(n = 14) 
• Other reasons (n = 3) 
Analyzed (n = 113) 
Excluded from analysis (n = 0) 
Give reasons:  incomplete data: (n = 2) 
Lost to follow-up (n = 0) 
Discontinued intervention 
(n = 1) 
Give reasons: did not receive 5 doses 
of the study drug due to error 
Allocated to intervention 
(n = 113) 
Received allocated intervention 
(n = 113) 
Did not receive allocated intervention 
(n = 0)
Lost to follow-up (n = 0) 
Discontinued intervention 
(n = 0)  
Allocated to CONTROLS 
(n = 116) 
Received placebo 
(n = 116) 
Did not receive placebo 
(n = 0) 
Analyzed (n = 116) 
Excluded from analysis (n = 2) 
Give reasons: incomplete data: (n = 2) 
Allocation 
Analysis 
Follow-Up 
Enrollment 
Was the subject randomized to 
receive intervention or control?
Figure 1 Flowchart (August 2005).
Table 2 Main Results
Lutein Placebo OR 95% CI p Value
Primary outcomes
Threshold ROP 7/113 (6.2%) 12/116 (10.3%) 0.60 0.24–1.46 0.18
NEC >2nd stage 2/113 (1.7%) 6/116 (5.1%) 0.34 0.07–1.66 0.15
BPD 5/113 (4.5%) 12/116 (10.3%) 0.43 0.15–1.17 0.07
Secondary outcomes
ROP all stages 23/113 (20.3%) 27/116 (23.2%) 0.87 0.53–1.43 0.35
Progression from ROP any stage to threshold ROP 7/23 (0.30) 12/27 (0.44) 0.68 0.32–1.44 0.23
Mortality (all-cause, prior to discharge) 3.8% 4.6% 0.72 0.22–1.59 0.89
Transfusions (mean  SD) 3.1  2 4.0  3 0.76 0.20–1.49 0.78
Hyperbilirubinemia >14.0 mg/dL 6/113 (5.3%) 7/116 (6.0%) 0.85 0.59–1.70 0.48
Late-onset sepsis 17.5% 20.3% 0.83 0.42–1.67 0.88
Severe (grade 3–4) intraventricular hemorrhage 4.0% 4.8% 0.85 0.36–1.88 0.90
Threshold ROP and/or BPD and/or NEC >2nd stage 13/113 (11.5%) 23/116 (19.8%) 0.580 0.30–1.08 0.08
BPD, bronchopulmonary dysplasia; CI, confidence interval; NEC, necrotizing enterocolitis; OR, odds ratio; ROP, retinopathy of prematurity; SD,
standard deviation.
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Our aim was to establish whether supplementation of
lutein + zeaxanthin is safe and helps prevent ROP, NEC, and
BPD inVLBWinfants. Unfortunately, the results are inconclusive.
ROP, NEC, and BPD manifested a decreasing trend in the
infants who received lutein + zeaxanthin (►Table 2). Supple-
mented infants had a 40% reduction in threshold ROP, a 52%
reduction in BPD, a 73% reduction inNEC, and a 35% reduction
in the rate of progression from stage I or II ROP to threshold
ROP. Although these decreases are not statistically significant,
they appear relevant and are consistent among the different
outcomes.
Of note, no pharmacodynamics/pharmacokinetics data are
available in literature to suggest optimal dosing, and we
identified the dosage to be used in this study on the basis
of the GRAS declaration-related documents,10 which do not
specifically refer to preterm infants. Therefore, we cannot
exclude that dosing should be increased to achieve a positive
effect in preterm infants whose risk for outcomes related to
oxidative stress is high.
We used the same dosage of lutein + zeaxanthin supple-
ments for all patients irrespective of the degree of prematu-
rity and of type of feeding (maternal, donor, formula milk, or
mixed). It would be interesting to understand whether these
variables should affect optimal dosage.
It is also possible that, although we enrolled over 200
infants, the sample size was still too small. This limitation is
inherent to the fact that this study to our knowledge is the
first of its kind.
The rationale for supplementing carotenoids in premature
infants is based on several points.
In the neonatal period, fresh, not-processed humanmilk is
the main dietary source of lutein and zeaxanthin,20,21 and
breast-fed infants have higher mean serum lutein concen-
trations than infants who consume formula unfortified with
lutein.20,22 It has been calculated that four times more lutein
is needed in infant formula than in human milk to achieve
similar serum lutein concentrations among breast-fed and
formula-fed infants.20
Carotenoids in human milk are a main player in an
antioxidative network of bioactive, human milk substances
that exert protective functions against oxidative stress. Dam-
age related to oxidative stress occurring in different periph-
eral tissues is an etiologic moment that is common to several
severe outcomes of prematurity such as ROP, NEC, and BPD.
Noteworthy, breast-feeding has been associated with lower
incidence rates of all of these outcomes.6,23
Lutein and all carotenoids provide relevant in vivo anti-
oxidative and anti–reactive oxygen species) activities
through inhibition of membrane lipids’ peroxidation and
scavenger radical-trapping activity and via a quenching effect
toward singlet and triplet oxygen.24–26 In addition, lutein and
zeaxanthin ensure protection against both light-induced
and metabolic oxidative damage in the retina and in other
developing tissues.
In a recent pilot RCT in healthy newborns, lutein adminis-
tration proved effective in increasing the levels of biological
antioxidant potential by decreasing the total hydroperoxides
as markers of oxidative stress.8 Plasma β-carotene concen-
trations have indeed been found to be lower in BPD infants,
which may result in a reduction of their antioxidant protec-
tion.27 Once more, in our study, the effect of lutein + zeaxan-
thin on prevention of BPD appears relevant, although not
statistically significant.
Clinical signs related to oxidative stressmay take years and
sometimes decades to becomemanifest. One limitation of our
study is that the outcomes were assessed at discharge or at
term-correctedgestational age,whichever camefirst. Itmight
beworthwhile extending the evaluation of possible effects on
health of early carotenoid supplementation to childhood and
adulthood. In adult humans, increased dietary intake of lutein
protects against the development of early atherosclerosis.28
In this study, lutein and zeaxanthin supplementation in
VLBW infants appeared well tolerated and not associated
with any adverse effect or putative toxicity. This is consistent
with similar safety findings in adults,29,30 where in some
studies much higher concentrations lutein/zeaxanthin were
in fact used.
In conclusion, this RCT does not clarify whether supple-
mentation of lutein and zeaxanthin since birth is associated
with decreased incidences of several multifactorial prematu-
rity outcomes related to oxidative stress occurring in the early
ages of life. The nonsignificant decreasing trends for ROP, NEC,
and BPD disclosed by our study should be confirmed in
further studies with adequately powered cohorts.
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